BRAF and neoplasm: Using 1010 matched case-control pairs within the NSHDS, we investigated circulating levels of insulin, C-peptide, adiponectin, and leptin in relation to the risk of CRC, and molecular subtypes of CRC defined by KRAS and BRAF mutation status and MSI status in the tumor.